Angelica sinensis is a Chinese medicinal root supplement used orally for menopausal comfort, circulation, and kidney preservation. In chronic kidney disease, oral use is linked to lower kidney failure and death, yet alone it alters neither sex hormones nor hot flashes; other benefits rely on multi-herb formulas or injections. Trials show good tolerance, though warfarin blood thinning, liver injury, breast cell growth, and species substitution remain key considerations. (Full Review)
| Marker | Target | Why |
|---|---|---|
| eGFR | ≥90 mL/min/1.73 m² (standard reference range) | Expected-change marker: tracks renal preservation and CKD slope (calculated from fasting serum creatinine and cystatin C) |
| Hemoglobin & Serum Iron | Hemoglobin: 13.5–17.5 g/dL men, 12.0–15.5 g/dL women; Serum iron: 60–170 μg/dL (standard reference range) | Expected-change marker: evaluates blood-building and iron-mobilizing response (paired with serum ferritin and transferrin saturation) |
| ALT & AST | ALT: 7–56 U/L; AST: 8–33 U/L (standard reference range) | Safety check: detects idiosyncratic herb-induced liver injury (discontinuation threshold >3× upper limit of normal) |
| PT / INR | INR 0.8–1.1 (standard reference range; or prescribed target on warfarin) | Safety check: detects anticoagulant potentiation when co-administered with vitamin K antagonists |
| Blood Pressure | No established target; change from individual baseline | Safety check: screens for rare transient blood pressure elevation |
Cadence: At baseline, at 4 weeks for liver transaminases (ALT/AST) and iron/hematology markers, and every 3–6 months during ongoing supplementation; seated resting blood pressure at baseline and during the first 2 weeks; PT/INR within 5–7 days of starting or stopping if co-administered with warfarin.